Connect with us

Markets & Industry

The End in Mind: exploring psychedelics and end-of-life experience

The free, virtual event will be open to the public and will take place on Thursday, 14 October.



Breaking Convention: bringing together leading minds in psychedelics

The End in Mind conference will bring together celebrities, healthcare and psychedelics experts and policy makers to explore the role that psychedelics can play in the end-of-life experience.

The event will discuss a number of different topics including psychedelic medicines and their uses, from age-old Indigenous practices to the latest clinical trials; the current and future role of psychedelics in care for serious illness, grief, and end-of-life experience; the science behind psychedelics and their potential to help treat mental, physical, and social conditions; stigmas surrounding the consumption of psychedelic substances; the policy landscape and emerging market for psychedelic medicines; and the growing movement to broaden access to these treatments.

Hosted by non-profit End Well, which is dedicated to the belief that all people should experience the end of life in a way that matches their values and goals, is the largest mainstream gathering to date dedicated to the future of psychedelic medicines in care for people facing serious illness or end of life.

GRAMMY® winner Melissa Etheridge, who will be speaking at the conference, said: “Finally, we seem to be moving past the stigma around plant medicines, and into a whole new era of understanding that will hopefully enable more of us to experience the benefits of these powerful medicines — especially in the most dire times of need when we are confronting illness, grief, mortality, existential fear, and death.”

Exploring psychedelics for end of life care

The End in Mind conference will bring together celebrities such as Dream Corps founder Van Jones, and healthcare, policy, culture, business and psychedelic leaders including American drug reformist and MAPS founder Rick Doblin.

See also  Delivery system enables administration of psychedelics without side effects

Other speakers include Stephen Ross, MD, psychiatrist, psychedelics researcher, and associate director of NYU Langone’s Center for Psychedelic Medicine; Ira Byock, MD, a leading palliative care physician and advocate for improving care through the end of life; Patricia James, Cheyenne pipe carrier and priest; Claire Bidwell Smith, an American therapist and best-selling author who specialises in grief therapy;  and many more.

“Psychedelics could be a paradigm shift in modern medicine, creating new possibilities that go beyond current treatments for life-limiting illness and allow people to live well until the end,” said Dr Shoshana Ungerleider, MD, founder of End Well. 

“Research indicates that when used in a carefully controlled and monitored environment, these medicines can offer a more person-centered, inclusive, and empathetic model for care for people facing the end of life — and that is something every one of us should be thinking about. The End in Mind will bring together many of the people and ideas shaping the future of this space, and make the promises and perils of these therapies accessible to a broader audience so as to spark meaningful conversations about what it means to end well.”

The speakers will lead interactive breakout sessions to answer questions and provide a deeper dive into the cultural, regulatory, and industry shifts shaping and being shaped by the psychedelic landscape.

Backed by leaders in psychedelics

The event is sponsored by leading companies in the psychedelics space, including: Palo Santo, a US-based psychedelic investment fund; Reset Pharma, which is advancing psilocybin therapy for patients with cancer and other life-threatening diagnosis; biotechnology company Cybin, the first psychedelics company to be listed on the New York Stock Exchange; atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders; and Microdose, a media platform with a vision to shift the world’s perception of psychedelic medicine.

See also  UK scientists to research use of psilocybin in end-of-life support

“It’s becoming increasingly clear that psychedelics are poised to change the field of mental health, and we are thrilled to be partners with the leading innovators in the space,” said Daniel Goldberg, co-founder and partner of Palo Santo. 

“As these medicines are increasingly destigmatised, medicalised and legalised, the time is right to invest in the future of this space and create broad access to effective treatments. From entrepreneurs to investors to practitioners to patients, we all have a role to play in realising the potential of psychedelics in healthcare.”

Doug Drysdale, CEO of Cybin, commented: “There is compelling research going back to the 1950s that psychedelic medicines can reduce pain and distress for people who are suffering.

“The End in Mind is focused on translating the research for a general audience, to make more people aware of the evidence base supporting these therapies and the recent advances in drug development and delivery.”

“For a variety of mental disorders affecting millions worldwide, the current standard of care simply isn’t adequate enough. Innovation is greatly needed – and psychedelics could play a substantial role in revolutionizing mental healthcare” added Florian Brand, CEO of atai. 

“However, to effectively communicate and integrate these medicines in the public domain, we must engage all stakeholders and foster the sort of dialogues organised by End Well.”

The free, virtual event will be open to the public and will take place on Thursday, 14 October from 11:45am to 5:00pm EDT/8:45am to 2:00pm PDT. Registration is free until 26 September.

To register for the event visit:

See also  LSD-like molecules may treat depression without the trip

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Markets & Industry

Psychedelic therapy programmes launch to address heartbreak, burnout and more



Psychedelic therapy programmes launch to address heartbreak, burnout and more

Mindbloom has launched its new Mastermind Series of psychedelic programmes for overcoming heartbreak, burnout and other unique mental health challenges. 

Led by and developed with leading experts in the field, each programme combines specialised teachings with ketamine therapy.

All programmes will include six ketamine therapy sessions focusing on a specific mental health issue, expert-led audio, video, and written content for preparation, treatment, and integration, practical tools such as meditation, one-on-one coaching and group integration sessions.

See also  Psychedelics for frontline workers, palliative care and eating disorders

The first programme in the Series is ‘Recovering from Rejection and Failure’, led by Dr Guy Winch who is a leading authority on emotional health, and a best-selling author and TED speaker whose talks have received over 30 million views.

Winch’s programme focuses on healing and preventing emotional injuries that people suffer in their personal, professional and romantic lives.

Mindbloom CEO and Founder Dylan Beynon stated: “More than 100 studies and 20 plus years of clinical use show that ketamine therapy may be the most transformational mental health treatment available today.

“In the face of epidemics of mental illness, addiction, and loneliness, we’re thrilled to offer our clients access to top experts across a range of issues – and to pair their expertise with our best-in-class ketamine therapy honed over hundreds of thousands of treatment sessions.”

“Emotional wounds like rejection and failure can be even more devastating than physical wounds, yet we don’t give them the same time and attention,” added Dr Winch.

“I’m thrilled to combine my techniques for emotional first aid with ketamine therapy, which has been shown to increase neuroplasticity and help build emotional resilience.”

Additional Mastermind programmes will be released in the coming months, including: Getting Unstuck, by Dr Elizabeth Lombardo; Beating Burnout, by Dr Shauna Shapiro; and Coping with Cravings, by Dr Jud Brewer

“Americans are struggling with heartbreak, burnout, and other challenges every day, and they’re looking for new tools to address them,” said Mindbloom’s Medical Director Dr Leonardo Vando.

“I’m grateful to these experts for providing Mindbloom’s clients with the unique practices and insights they’ve cultivated during their distinguished careers, to help them overcome the biggest obstacles in their lives.”

Continue Reading

Markets & Industry

Mychedelica launches to revolutionise psychedelic medicine



Mychedelica launches to revolutionise psychedelic medicine

A new company specialising in psychedelic medicine – mychedelica – is offering a comprehensive suite of services to support the advancement of this transformative field. 

With a team of experienced medical writers and research support specialists, mychedelica is committed to providing the highest quality services to researchers, clinicians, and pharmaceutical companies working in the psychedelic medicine space.

Psychedelic medicine is rapidly gaining recognition for its potential to treat a wide range of mental health conditions, including depression, anxiety, addiction, and post-traumatic stress disorder (PTSD). However, the field is still in its early stages of development, and there is a critical need for high-quality medical writing and research support services to facilitate its progress.

CEO of mychedelica, Bilal Bham, commented: “We are thrilled to launch mychedelica and contribute to the advancement of psychedelic medicine.

“Our team of experienced professionals is dedicated to providing the highest quality services to researchers, clinicians, and pharmaceutical companies working in this groundbreaking field.”

mychedelica provides a comprehensive range of services, including:

Medical writing: Experienced medical writers will craft clinical trial protocols, regulatory submissions, and peer-reviewed publications, ensuring that research findings are communicated clearly and effectively.

Funding research support: Experts in grant writing and fundraising strategies will assist researchers in securing funding for their psychedelic medicine studies.

Regulatory consulting: mychedelica’s team of regulatory experts will navigate the complex regulatory landscape surrounding psychedelic medicine, ensuring that clinical trials and products comply with all applicable laws and regulations.

With its commitment to quality and innovation, mychedelica is poised to play a pivotal role in shaping the future of psychedelic medicine. The company’s services will empower researchers to conduct rigorous clinical trials, clinicians to provide effective treatments, and pharmaceutical companies to develop safe and effective psychedelic medicines.

Continue Reading

Markets & Industry

Short Wave Pharma: innovating eating disorder care with psychedelics



Short Wave Pharma: innovating eating disorder care psychedelics

Psychedelic Health speaks to Short Wave Pharma CEO Rivki Stern about the company’s plans to innovate eating disorder care through psychedelics and its recent acquisition by Psych Capital.

Short Wave Pharma was recently acquired by global investment firm Psych Capital. The companies are on a mission to transform mental health care, focusing on innovative approaches and treatments, including psychedelics, which are increasingly gaining acceptability as clinical research results accumulate.

Short Wave Pharma’s clinical programmes are particularly focused on Anorexia nervosa – a complex mental health condition with one of the highest fatality rates. Despite the condition being associated with high rates of suicide, it is a hugely underserved area of mental health, with no FDA-approved pharmacological drug, and a high rate of chronicity. 

See also  Psych Capital completes acquisition of Short Wave Pharma

The company has developed a novel delivery method and drug combination specifically designed to address the requirements of this vulnerable population. Short Wave focuses on methods of delivery that will be effective for Anorexia, which is a metabolic disease as well as a mental health condition. Its unique buccal film delivery method is intended to affect the brain while bypassing the liver and gut degradation through mucoadhesive absorption.

“Our goal is to alleviate, solve, and treat mental health conditions. It’s a dire need in our global society, and it’s constantly on the rise,” commented Stern. “Eating disorders are a very good example of that and we have seen a very alarming growth since COVID. 

“What drew our attention to psychedelics is that they have the potential to address very complex mental health diseases and have been designated by FDA as breakthrough medicine for life-threatening conditions.

“Because there are no current solutions, we must harness very innovative approaches and potential solutions. That’s why we started working with psychedelics which may be difficult because they are not regulated, but we don’t shy away from challenges.”

The company’s drug is based on psilocybin and another API which together utilise an expanded mechanism of action and a therapeutic effect superior to psilocybin alone, impacting more than one group of receptors in the brain. 

The delivery method is sensitive to the patients’ needs – who may not want to swallow or be injected – and is known for its high bioavailability. 

“By mucosal absorption, we are speeding the onset of the medicine and amplifying the impact which will help tackle the patients’ metabolic challenges and improve acceptance,” says Stern. 

The drug product and delivery method are currently in preparation for Phase 1 clinical studies, and in its current preclinical studies, the company is validating its delivery and expanded mechanisms of action. So far, initial safety results are positive, with a further, more in-depth toxicity study taking place. 

Psych Capital – which is a public investment and awareness platform for mental health, and has a portfolio of innovative companies – has supported Short Wave Pharma’s IP-driven approach to eating disorder care through its recent acquisition of the company.

Short Wave and Psych Capital say they are aligned in their missions to innovate mental healthcare and deliver transformative care in areas of high unmet need.

Stern commented: “We all share a passion for innovation and together have decades of experience in evaluating investments as well as scaling up R&D projects and start-ups in life sciences. 

“We have a shared commitment to alleviate the suffering from mental health. Every one of us has experienced the frustration and challenges of dealing with mental health issues.

“Together, we’re going to put this commitment into action, by bringing forth innovative solutions and developments and getting them through the first stages of development, from discovery through to early phases of clinical study. 

“With psychedelics components, this is extra challenging because of their status as scheduled drugs within a still evolving regulatory framework, which adds uncertainty to the drug development process. 

“Short Wave Pharma has operational expertise in early-stage drug development which will bring extra value to the group’s projects as they develop through our funnel and grow into promising candidates for mental healthcare.  

“We want to identify the gems, guide them through clinical development, and create the right network to attract the right partners for further development and commercialisation.”

Short Wave Pharma is planning to enter its treatment into clinical studies in 2024.

Continue Reading